A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Status:
Completed
Trial end date:
2012-10-08
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent
OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who
received at least 1 but no more than 2 prior drug regimens